Uncategorized

An experimental hormone therapy delays the spread of prostate cancer that has stopped responding to standard treatment, according to new clinical trial results. The drug, called apalutamide, reduced the risk of either the cancer spreading or death by over 70%. Patients taking apalutamide lived without their cancer spreading (metastasis) for over three years on average, compared to 16 months for those taking placebo. Professor Malcolm Mason, Cancer Research UK’s prostate cancer expert, said the results were “very welcome” because clinical trials have been badly needed for these patients. The study was published in the New England Journal of Medicine and presented at the 2018 Genitourinary Cancers Symposium in San Francisco.

See original article at: https://www.cancerresearchuk.org/about-us/cancer-news/news-report/2018-02-09-apalutamide-delays-spread-of-certain-prostate-cancers-in-trial